Investigation of nanoparticles using magnetic resonance imaging after intravitreal injection

Raju, Hemalatha B.; Hu, Ying; Padgett, Kyle R.; Rodríguez, José E.; Goldberg, Jeffrey L.

doi:10.1111/j.1442-9071.2011.02651.x

Cited by 23 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the magnetic HCECs could be moved within a magnetic field (data under review). The absence of magnetic nanoparticle toxicity on HCECs in vitro matched our published data on a lack of toxicity when the nanoparticles were injected into rodent eyes in vivo [118,119]. By targeting injected HCECs to the endothelium with a uniform magnetic field, this cell therapy approach may decrease the potential risks of adverse effects such as trabecular meshwork clogging and increased intraocular pressure.…”

Section: Cell Replacement Therapies To Treat Corneal Endotheliumsupporting

confidence: 77%

Regenerative Cell Therapy for Corneal Endothelium

Bartáková

Kunzevitzky

Goldberg

2014

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Endothelial cell dysfunction as in Fuchs dystrophy or pseudophakic bullous keratopathy, and the limited regenerative capacity of human corneal endothelial cells (HCECs), drive the need for corneal transplant. In response to limited donor corneal availability, significant effort has been directed towards cell therapy as an alternative to surgery. Stimulation of endogenous progenitors, or transplant of stem cell-derived HCECs or in vitro-expanded, donor-derived HCECs could replace traditional surgery with regenerative therapy. Ex vivo expansion of HCECs is technically challenging, and the basis for molecular identification of functional HCECs is not established. Delivery of cells to the inner layer of the human cornea is another challenge: different techniques, from simple injection to artificial corneal scaffolds, are being investigated. Despite remaining questions, corneal endothelial cell therapies, translated to the clinic, represent the future for the treatment of corneal endotheliopathies.

show abstract

Section: Cell Replacement Therapies To Treat Corneal Endotheliumsupporting

confidence: 77%

Regenerative Cell Therapy for Corneal Endothelium

Bartáková

Kunzevitzky

Goldberg

2014

Curr Ophthalmol Rep

View full text Add to dashboard Cite

show abstract

“…Other injection routes such as intra-peritoneal (IP) 255-257 , retroorbital, 51, 58 , intravitreal (inner cavity of the eyes for intraocular drug delivery), 258, 259 intra-muscular and subcutaneous injections have also been used as alternative methods for administration of the IONPs. Tsuchiya et al .…”

Section: Ionps Pharmacokineticsmentioning

confidence: 99%

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

et al. 2015

View full text Add to dashboard Cite

Iron oxide nanoparticles (IONPs) have been extensively used during the last two decades, either as effective bio-imaging contrast agents or as carriers of biomolecules such as drugs, nucleic acids and peptides for controlled delivery to specific organs and tissues. Most of these novel applications require elaborate tuning of the physiochemical and surface properties of the IONPs. As new IONPs designs are envisioned, synergistic consideration of the body's innate biological barriers against the administered nanoparticles and the short and long-term side effects of the IONPs become even more essential. There are several important criteria (e.g. size and size-distribution, charge, coating molecules, and plasma protein adsorption) that can be effectively tuned to control the in vivo pharmacokinetics and biodistribution of the IONPs. This paper reviews these crucial parameters, in light of biological barriers in the body, and the latest IONPs design strategies used to overcome them. A careful review of the long-term biodistribution and side effects of the IONPs in relation to nanoparticle design is also given. While the discussions presented in this review are specific to IONPs, some of the information can be readily applied to other nanoparticle systems, such as gold, silver, silica, calcium phosphates and various polymers.

show abstract

“…Movement of particles from the vitreous into the surrounding ocular tissues also differed depending on size with larger microparticles shown to travel to the trabecular meshwork, whereas smaller nanoparticles moved to the trabecular meshwork and to the retina. In addition to this work, a recent study by Raju et al (2012) demonstrated differences in the elimination of iron oxide particles after intravitreal injection. 47 Larger (4 mm) iron oxide particles coated with polystyrene were shown by magnetic resonance imaging (MRI) to remain in the rat eye 5 weeks following administration, whereas smaller (50 nm) iron oxide particles coated with dextran were not found to reside in the eye after 5 weeks.…”

Section: Effect Of Nanoparticle Sizementioning

confidence: 82%

“…In addition to this work, a recent study by Raju et al (2012) demonstrated differences in the elimination of iron oxide particles after intravitreal injection. 47 Larger (4 mm) iron oxide particles coated with polystyrene were shown by magnetic resonance imaging (MRI) to remain in the rat eye 5 weeks following administration, whereas smaller (50 nm) iron oxide particles coated with dextran were not found to reside in the eye after 5 weeks. This data seems somewhat conflicting with the work by Sakurai and colleagues (2001), 46 where the residence time increased with decreased size.…”

Section: Effect Of Nanoparticle Sizementioning

confidence: 82%

“…It is difficult to directly compare the movement of these iron oxide particles as a function of size, due to the difference in the applied polymer coating and its role in the elimination rate of the particles. 47 Since nanoparticles formulated for drug delivery are regarded to be within the size range of 10 nm up to 1000 nm, 48 the impact of size alone on nanoparticle movement to the posterior eye is unlikely to be the main controlling factor, with a range of nanoparticles from 50 nm 46 up to 643 nm 47 of different composition shown to penetrate through the retina following intravitreal injection. It is likely that movement through the vitreous involves a combination of both the right size and the optimal surface characteristics.…”

Section: Effect Of Nanoparticle Sizementioning

confidence: 99%

See 1 more Smart Citation

The Vitreous Humor As a Barrier to Nanoparticle Distribution

Mains

Wilson

2013

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

The vitreous humor represents a significant barrier to the penetration of nanoparticulate-based ocular drug delivery systems. The gel structure and biochemical components of the vitreous will impact the rate of nanoparticle movement through the tissue to reach the retinal tissue. Also the structure of the vitreous, flow systems operating within it, age-related structural changes, and the presence of inflammation will also have a potential effect on movement. To effectively target the posterior retina, the physical properties of the nanoparticle formulation are a key element in the design of a system that will penetrate through the vitreous barrier.

show abstract

Investigation of nanoparticles using magnetic resonance imaging after intravitreal injection

Abstract: Background: Magnetic nanoparticles may be used for focal delivery for cells, plasmids or drugs, and other applications. Here we asked whether magnetic nanoparticles could be detected in vivo at different time points after intravitreal injection by magnetic resonance imaging.

Cited by 23 publications

References 21 publications

Regenerative Cell Therapy for Corneal Endothelium

Regenerative Cell Therapy for Corneal Endothelium

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

The Vitreous Humor As a Barrier to Nanoparticle Distribution

Contact Info

Product

Resources

About